Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma

More effective treatments are needed for low-grade serous ovarian carcinoma (LGSOC). Our patient, who suffers from metastatic LGSOC, had received all established treatments. Sequencing analysis revealed an activating BRAF mutation. Therefore, combined treatment with BRAF and MEK inhibitors, which is...

Descripción completa

Detalles Bibliográficos
Autores principales: Tholander, Bengt, Koliadi, Anthoula, Botling, Johan, Dahlstrand, Hanna, Von Heideman, Anne, Ahlström, Håkan, Öberg, Kjell, Ullenhag, Gustav J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594849/
https://www.ncbi.nlm.nih.gov/pubmed/33043759
http://dx.doi.org/10.1080/03009734.2020.1826612
_version_ 1783601711653322752
author Tholander, Bengt
Koliadi, Anthoula
Botling, Johan
Dahlstrand, Hanna
Von Heideman, Anne
Ahlström, Håkan
Öberg, Kjell
Ullenhag, Gustav J.
author_facet Tholander, Bengt
Koliadi, Anthoula
Botling, Johan
Dahlstrand, Hanna
Von Heideman, Anne
Ahlström, Håkan
Öberg, Kjell
Ullenhag, Gustav J.
author_sort Tholander, Bengt
collection PubMed
description More effective treatments are needed for low-grade serous ovarian carcinoma (LGSOC). Our patient, who suffers from metastatic LGSOC, had received all established treatments. Sequencing analysis revealed an activating BRAF mutation. Therefore, combined treatment with BRAF and MEK inhibitors, which is the gold standard in malignant melanoma, was initiated. After eight months of therapy, the response was assessed as complete and the treatment is still, 3.5 years after initiation, of benefit. To our knowledge, no complete response on combined BRAF and MEK inhibitor treatment of low-grade serous ovarian cancer has previously been reported.
format Online
Article
Text
id pubmed-7594849
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-75948492020-11-10 Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma Tholander, Bengt Koliadi, Anthoula Botling, Johan Dahlstrand, Hanna Von Heideman, Anne Ahlström, Håkan Öberg, Kjell Ullenhag, Gustav J. Ups J Med Sci Case Report More effective treatments are needed for low-grade serous ovarian carcinoma (LGSOC). Our patient, who suffers from metastatic LGSOC, had received all established treatments. Sequencing analysis revealed an activating BRAF mutation. Therefore, combined treatment with BRAF and MEK inhibitors, which is the gold standard in malignant melanoma, was initiated. After eight months of therapy, the response was assessed as complete and the treatment is still, 3.5 years after initiation, of benefit. To our knowledge, no complete response on combined BRAF and MEK inhibitor treatment of low-grade serous ovarian cancer has previously been reported. Taylor & Francis 2020-10-10 /pmc/articles/PMC7594849/ /pubmed/33043759 http://dx.doi.org/10.1080/03009734.2020.1826612 Text en © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Tholander, Bengt
Koliadi, Anthoula
Botling, Johan
Dahlstrand, Hanna
Von Heideman, Anne
Ahlström, Håkan
Öberg, Kjell
Ullenhag, Gustav J.
Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma
title Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma
title_full Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma
title_fullStr Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma
title_full_unstemmed Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma
title_short Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma
title_sort complete response with combined braf and mek inhibition in braf mutated advanced low-grade serous ovarian carcinoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594849/
https://www.ncbi.nlm.nih.gov/pubmed/33043759
http://dx.doi.org/10.1080/03009734.2020.1826612
work_keys_str_mv AT tholanderbengt completeresponsewithcombinedbrafandmekinhibitioninbrafmutatedadvancedlowgradeserousovariancarcinoma
AT koliadianthoula completeresponsewithcombinedbrafandmekinhibitioninbrafmutatedadvancedlowgradeserousovariancarcinoma
AT botlingjohan completeresponsewithcombinedbrafandmekinhibitioninbrafmutatedadvancedlowgradeserousovariancarcinoma
AT dahlstrandhanna completeresponsewithcombinedbrafandmekinhibitioninbrafmutatedadvancedlowgradeserousovariancarcinoma
AT vonheidemananne completeresponsewithcombinedbrafandmekinhibitioninbrafmutatedadvancedlowgradeserousovariancarcinoma
AT ahlstromhakan completeresponsewithcombinedbrafandmekinhibitioninbrafmutatedadvancedlowgradeserousovariancarcinoma
AT obergkjell completeresponsewithcombinedbrafandmekinhibitioninbrafmutatedadvancedlowgradeserousovariancarcinoma
AT ullenhaggustavj completeresponsewithcombinedbrafandmekinhibitioninbrafmutatedadvancedlowgradeserousovariancarcinoma

Ejemplares similares